Scholarlink

Introduction <p>Combining ezetimibe (EZ) and statins is recommended for the treatment of elevated low-density lipoprotein-cholesterol (LDL-C). This subgroup analysis evaluated the efficacy of fixed-dose combination (FDC) therapy with EZ and atorvastatin (AS) versus AS monotherapy on attaining LDL-C goals in Chinese patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) grouped by ASCVD risk, age, and sex.</p> Methods <p>Data from the phase&#xa0;III, randomized, double-blind study (NCT03768427) compared EZ10/AS10&#xa0;mg FDC versus AS20&#xa0;mg (cohort&#xa0;A), and EZ10/AS20&#xa0;mg FDC versus AS40&#xa0;mg monotherapy (cohort&#xa0;B) in Chinese patients with uncontrolled hypercholesterolemia. Proportions of patients attaining 2016 Chinese guideline-recommended LDL-C goals (low/medium risk [&lt; 130&#xa0;mg/dL], high risk [&lt; 100&#xa0;mg/dL], very high risk [&lt; 70&#xa0;mg/dL]) were assessed at weeks&#xa0;6 and 12. Subgroup analyses by ASCVD risk, age (&lt; 65 and ≥ 65&#xa0;years), and sex were conducted.</p> Results <p>LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week&#xa0;12 (cohort&#xa0;A: 62.7% vs. 35.1%, <i>P</i> = 0.0009; cohort&#xa0;B: 67.5% vs. 31.0%, <i>P</i> &lt; 0.0001). A greater proportion of patients with very high ASCVD risk attained LDL-C goals with FDCs versus AS monotherapy at week&#xa0;12 (cohort&#xa0;A: 62.3% vs. 33.9%; cohort&#xa0;B: 69.1% vs. 29.5%). LDL-C goal attainment was higher with FDCs versus individual doses of AS at weeks&#xa0;6 and 12 in both cohorts, regardless of age or sex.</p> Conclusion <p>FDCs significantly improved LDL-C goal attainment compared to AS monotherapy in patients with very high ASCVD risk. In the subgroups by age and sex, a higher proportion of patients with uncontrolled hypercholesterolemia attained their LDL-C goals.</p> Trial Registry <p>Trial registration number NCT03768427.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月19日

查看全文
  • Juying Qian,
  • Xuelian Zhang,
  • Jiyan Chen,
  • Chunhua Ding,
  • Ping Yang,
  • Li Qing,
  • Yan Liu,
  • Si Si Chen,
  • Junbo Ge

摘要

Introduction

Combining ezetimibe (EZ) and statins is recommended for the treatment of elevated low-density lipoprotein-cholesterol (LDL-C). This subgroup analysis evaluated the efficacy of fixed-dose combination (FDC) therapy with EZ and atorvastatin (AS) versus AS monotherapy on attaining LDL-C goals in Chinese patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) grouped by ASCVD risk, age, and sex.

Methods

Data from the phase III, randomized, double-blind study (NCT03768427) compared EZ10/AS10 mg FDC versus AS20 mg (cohort A), and EZ10/AS20 mg FDC versus AS40 mg monotherapy (cohort B) in Chinese patients with uncontrolled hypercholesterolemia. Proportions of patients attaining 2016 Chinese guideline-recommended LDL-C goals (low/medium risk [< 130 mg/dL], high risk [< 100 mg/dL], very high risk [< 70 mg/dL]) were assessed at weeks 6 and 12. Subgroup analyses by ASCVD risk, age (< 65 and ≥ 65 years), and sex were conducted.

Results

LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week 12 (cohort A: 62.7% vs. 35.1%, P = 0.0009; cohort B: 67.5% vs. 31.0%, P < 0.0001). A greater proportion of patients with very high ASCVD risk attained LDL-C goals with FDCs versus AS monotherapy at week 12 (cohort A: 62.3% vs. 33.9%; cohort B: 69.1% vs. 29.5%). LDL-C goal attainment was higher with FDCs versus individual doses of AS at weeks 6 and 12 in both cohorts, regardless of age or sex.

Conclusion

FDCs significantly improved LDL-C goal attainment compared to AS monotherapy in patients with very high ASCVD risk. In the subgroups by age and sex, a higher proportion of patients with uncontrolled hypercholesterolemia attained their LDL-C goals.

Trial Registry

Trial registration number NCT03768427.